Which adverse effects influence the dropout rate in selective serotonin reuptake inhibitor (SSRI) treatment? Results for 50,824 patients;Welche unerwünschten ereignisse haben einen einfluss auf die behandlungsabbruchrate von selektiven serotonin-wiederaufnahmehemmern (SSRI)? Ergebnis von 50.824 patienten

GMS German Medical Science

Volumn 12, Issue , 2014, Pages 1-8

  Kostev, Karel ^a   Rex, Juliana ^a   Eith, Thilo ^b   Heilmaier, Christina ^c  

^a IQVIA   (United States)

^b FRESENIUS UNIVERSITY OF APPLIED SCIENCES   (Germany)

^c FOM UNIVERSITY OF APPLIED SCIENCES   (Germany)

Author keywords

Adverse drug reactions; Antidepressants; Dropout; Selective serotonin reuptake inhibitors

Indexed keywords

ANTIDEPRESSANT AGENT; SEROTONIN UPTAKE INHIBITOR;

ADULT; AGE; AGED; CHEMICALLY INDUCED; DEPRESSIVE DISORDER, MAJOR; DIGESTIVE SYSTEM DISEASE; FEMALE; HEART ARRHYTHMIA; HUMAN; MALE; MEDICATION COMPLIANCE; MIDDLE AGED; PSYCHOLOGY; RISK FACTOR; SLEEP DISORDER; STATISTICS AND NUMERICAL DATA; VERY ELDERLY;

ADULT; AGE FACTORS; AGED; AGED, 80 AND OVER; ANTIDEPRESSIVE AGENTS; ARRHYTHMIAS, CARDIAC; DEPRESSIVE DISORDER, MAJOR; DIGESTIVE SYSTEM DISEASES; FEMALE; HUMANS; MALE; MEDICATION ADHERENCE; MIDDLE AGED; RISK FACTORS; SEROTONIN UPTAKE INHIBITORS; SLEEP WAKE DISORDERS;

EID: 84908067335     PISSN: None     EISSN: 16123174     Source Type: Journal    
DOI: 10.3205/000200     Document Type: Article

References (42)

1. Gordon M, Melvin G. Selective serotonin re-uptake inhibitors--a review of the side effects in adolescents. Aust Fam Physician. 2013 Sep;42(9):620-3.
2. Vaswani M, Linda FK, Ramesh S. Role of selective serotonin reuptake inhibitors in psychiatric disorders: a comprehensive review. Prog Neuropsychopharmacol Biol Psychiatry. 2003 Feb;27(1):85-102. DOI: 10.1016/S0278-5846(02)00338-X
3. Nash J, Nutt D. Antidepressants. Psychiatry. 2007;(6):289-94.
4. Wenthur CJ, Bennett MR, Lindsley CW. Classics in chemical neuroscience: fluoxetine (Prozac). ACS Chem Neurosci. 2014 Jan 15;5(1):14-23. DOI: 10.1021/cn400186j
5. Cipriani A, Furukawa TA, Salanti G, Geddes JR, Higgins JP, Churchill R, Watanabe N, Nakagawa A, Omori IM, McGuire H, Tansella M, Barbui C. Comparative efficacy and acceptability of 12 new-generation antidepressants: a multiple-treatments metaanalysis. Lancet. 2009 Feb 28;373(9665):746-58. DOI: 10.1016/S0140-6736(09)60046-5
6. Andrade C. Selective serotonin reuptake inhibitor drug interactions in patients receiving statins. J Clin Psychiatry. 2014 Feb;75(2):e95-9. DOI: 10.4088/JCP.13f08941
7. Holland J, Bhogle M. Sertraline and mirtazapine as geriatric antidepressants. Psychiatr Danub. 2013 Sep;25 Suppl 2:S286- 90.
8. Westenberg HG, Sandner C. Tolerability and safety of fluvoxamine and other antidepressants. Int J Clin Pract. 2006 Apr;60(4):482-91. DOI: 10.1111/j.1368-5031.2006.00865.x
9. Becher H, Kostev K, Schröder-Bernhardi D. Validity and representativeness of the "Disease Analyzer" patient database for use in pharmacoepidemiological and pharmacoeconomic studies. Int J Clin Pharmacol Ther. 2009 Oct;47(10):617-26. DOI: 10.5414/CPP47617
10. Ogdie A, Langan S, Parkinson J, Dattani H, Kostev K, Gelfand JM. Medical Record Databases. In: Strom BL, Kimmel SE, Hennessy S, editors. Pharmacoepidemiology. 5th ed. Oxford, UK: Wiley-Blackwell; 2012. p. 224-43. DOI: 10.1002/9781119959946.ch15
11. Henneicke-von Zepelin HH, Meden H, Kostev K, Schröder- Bernhardi D, Stammwitz U, Becher H. Isopropanolic black cohosh extract and recurrence-free survival after breast cancer. Int J Clin Pharmacol Ther. 2007 Mar;45(3):143-54.
12. Ziller M, Ziller V, Haas G, Rex J, Kostev K. Risk of venous thrombosis in users of hormonal contraceptives in German gynaecological practices: a patient database analysis. Arch Gynecol Obstet. 2014 Feb;289(2):413-9. DOI: 10.1007/s00404-013-2983-9
13. Martin A, Young C, Leckman JF, Mukonoweshuro C, Rosenheck R, Leslie D. Age effects on antidepressant-induced manic conversion. Arch Pediatr Adolesc Med. 2004 Aug;158(8):773-80. DOI: 10.1001/archpedi.158.8.773
14. Quan H, Sundararajan V, Halfon P, Fong A, Burnand B, Luthi JC, Saunders LD, Beck CA, Feasby TE, Ghali WA. Coding algorithms for defining comorbidities in ICD-9-CM and ICD-10 administrative data. Med Care. 2005 Nov;43(11):1130-9. DOI: 10.1097/01.mlr.0000182534.19832.83
15. Garfield LD, Dixon D, Nowotny P, Lotrich FE, Pollock BG, Kristjansson SD, Doré PM, Lenze EJ. Common selective serotonin reuptake inhibitor side effects in older adults associated with genetic polymorphisms in the serotonin transporter and receptors: data from a randomized controlled trial. Am J Geriatr Psychiatry. 2014 Oct;22(10):971-9. DOI: 10.1016/j.jagp.2013.07.003
16. Giorlando F, Teister J, Dodd S, Udina M, Berk M. Hyponatraemia: an audit of aged psychiatry patients taking SSRIs and SNRIs. Curr Drug Saf. 2013 Jul;8(3):175-80. DOI: 10.2174/15748863113089990036
17. Lorgunpai SJ, Grammas M, Lee DS, McAvay G, Charpentier P, Tinetti ME. Potential therapeutic competition in community-living older adults in the U.S.: use of medications that may adversely affect a coexisting condition. PLoS ONE. 2014;9(2):e89447. DOI: 10.1371/journal.pone.0089447
18. Schellander R, Donnerer J. Antidepressants: clinically relevant drug interactions to be considered. Pharmacology. 2010;86(4):203-15. DOI: 10.1159/000319744
19. Ho JM, Gomes T, Straus SE, Austin PC, Mamdani M, Juurlink DN. Adverse cardiac events in older patients receiving venlafaxine: a population-based study. J Clin Psychiatry. 2014 Jun;75(6):e552-8. DOI: 10.4088/JCP.13m08508
20. Kemp AH, Brunoni AR, Santos IS, Nunes MA, Dantas EM, Carvalho de Figueiredo R, Pereira AC, Ribeiro AL, Mill JG, Andreão RV, Thayer JF, Benseñor IM, Lotufo PA. Effects of Depression, Anxiety, Comorbidity, and Antidepressants on Resting-State Heart Rate and Its Variability: An ELSA-Brasil Cohort Baseline Study. Am J Psychiatry. 2014 Aug. DOI: 10.1176/appi.ajp.2014.13121605
21. Meijer WE, Heerdink ER, van Eijk JT, Leufkens HG. Adverse events in users of sertraline: results from an observational study in psychiatric practice in The Netherlands. Pharmacoepidemiol Drug Saf. 2002 Dec;11(8):655-62. DOI: 10.1002/pds.752
22. Degner D, Grohmann R, Kropp S, Rüther E, Bender S, Engel RR, Schmidt LG. Severe adverse drug reactions of antidepressants: results of the German multicenter drug surveillance program AMSP. Pharmacopsychiatry. 2004 Mar;37 Suppl 1:S39-45. DOI: 10.1055/s-2004-815509
23. Wernicke J, Pangallo B, Wang F, Murray I, Henck JW, Knadler MP, D'Souza DN, Uetrecht JP. Hepatic effects of duloxetine-I: non-clinical and clinical trial data. Curr Drug Saf. 2008 May;3(2):132-42. DOI: 10.2174/157488608784529189
24. Murata Y, Kamishioiri Y, Tanaka K, Sugimoto H, Sakamoto S, Kobayashi D, Mine K. Severe sleepiness and excess sleep duration induced by paroxetine treatment is a beneficial pharmacological effect, not an adverse reaction. J Affect Disord. 2013 Sep;150(3):1209-12. DOI: 10.1016/j.jad.2013.05.040
25. Sarganas G, Garbe E, Klimpel A, Hering RC, Bronder E, Haverkamp W. Epidemiology of symptomatic drug-induced long QT syndrome and Torsade de Pointes in Germany. Europace. 2014 Jan;16(1):101-8. DOI: 10.1093/europace/eut214
26. Ishak WW, Christensen S, Sayer G, Ha K, Li N, Miller J, Nguyen JM, Cohen RM. Sexual satisfaction and quality of life in major depressive disorder before and after treatment with citalopram in the STAR*D study. J Clin Psychiatry. 2013 Mar;74(3):256-61. DOI: 10.4088/JCP.12m07933
27. Keltner NL, McAfee KM, Taylor CL. Mechanisms and treatments of SSRI-induced sexual dysfunction. Perspect Psychiatr Care. 2002 Jul-Sep;38(3):111-6. DOI: 10.1111/j.1744-6163.2002.tb00665.x
28. Trenque T, Maura G, Herlem E, Vallet C, Sole E, Auriche P, Drame M. Reports of sexual disorders related to serotonin reuptake inhibitors in the French pharmacovigilance database: an example of underreporting. Drug Saf. 2013 Jul;36(7):515-9. DOI: 10.1007/s40264-013-0069-z
29. Jeong BO, Kim SW, Kim SY, Kim JM, Shin IS, Yoon JS. Use of serotonergic antidepressants and bleeding risk in patients undergoing surgery. Psychosomatics. 2014 May-Jun;55(3):213-20. DOI: 10.1016/j.psym.2013.08.011
30. Wang YP, Chen YT, Tsai CF, Li SY, Luo JC, Wang SJ, Tang CH, Liu CJ, Lin HC, Lee FY, Chang FY, Lu CL. Short-term use of serotonin reuptake inhibitors and risk of upper gastrointestinal bleeding. Am J Psychiatry. 2014 Jan;171(1):54-61. DOI: 10.1176/appi.ajp.2013.12111467
31. Seifert CF, Wiltrout TR. Calcaneal bone mineral density in young adults prescribed selective serotonin reuptake inhibitors. Clin Ther. 2013 Sep;35(9):1412-7. DOI: 10.1016/j.clinthera.2013.07.423
32. Bruyère O, Reginster JY. Osteoporosis in patients taking selective serotonin reuptake inhibitors: a focus on fracture outcome. Endocrine. 2014 Aug. DOI: 10.1007/s12020-014-0357-0
33. Staeker J, Leucht S, Laika B, Steimer W. Polymorphisms in serotonergic pathways influence the outcome of antidepressant therapy in psychiatric inpatients. Genet Test Mol Biomarkers. 2014 Jan;18(1):20-31. DOI: 10.1089/gtmb.2013.0217
34. Maina G, Albert U, Salvi V, Bogetto F. Weight gain during longterm treatment of obsessive-compulsive disorder: a prospective comparison between serotonin reuptake inhibitors. J Clin Psychiatry. 2004 Oct;65(10):1365-71. DOI: 10.4088/JCP.v65n1011
35. Caccia S. Metabolism of the newest antidepressants: comparisons with related predecessors. IDrugs. 2004 Feb;7(2):143-50.
36. Nurnberg HG, Thompson PM, Hensley PL. Antidepressant medication change in a clinical treatment setting: a comparison of the effectiveness of selective serotonin reuptake inhibitors. J Clin Psychiatry. 1999 Sep;60(9):574-9. DOI: 10.4088/JCP.v60n0902
37. Zivin K, Pfeiffer PN, Bohnert AS, Ganoczy D, Blow FC, Nallamothu BK, Kales HC. Evaluation of the FDA warning against prescribing citalopram at doses exceeding 40 mg. Am J Psychiatry. 2013 Jun;170(6):642-50. DOI: 10.1176/appi.ajp.2013.12030408
38. Markowitz JS, Donovan JL, DeVane CL, Taylor RM, Ruan Y, Wang JS, Chavin KD. Effect of St John's wort on drug metabolism by induction of cytochrome P450 3A4 enzyme. JAMA. 2003 Sep;290(11):1500-4. DOI: 10.1001/jama.290.11.1500
39. Dobry Y, Braquehais MD, Sher L. Bullying, psychiatric pathology and suicidal behavior. Int J Adolesc Med Health. 2013;25(3):295-9. DOI: 10.1515/ijamh-2013-0065
40. Harvey BH, Slabbert FN. New insights on the antidepressant discontinuation syndrome. Hum Psychopharmacol. 2014 Aug. DOI: 10.1002/hup.2429
41. Clouston SA, Rubin MS, Colen CG, Link BG. Social inequalities in suicide: the role of selective serotonin reuptake inhibitors. Am J Epidemiol. 2014 Oct;180(7):696-704. DOI: 10.1093/aje/kwu191
42. Kaddurah-Daouk R, Weinshilboum RM; Pharmacometabolomics Research Network. Pharmacometabolomics: implications for clinical pharmacology and systems pharmacology. Clin Pharmacol Ther. 2014 Feb;95(2):154-67. DOI: 10.1038/clpt.2013.217